KVKarmele Valencia

Karmele Valencia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karmele Valencia has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Ane Álava

    Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain

    2 shared publications
  • Beñat Picabea

    Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red, Cáncer (CIBERONC), Madrid, Spain

    2 shared publications
  • Cristina Viu-Idocin

    Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain

    2 shared publications
  • Elizabeth Guruceaga

    Bioinformatics Platform, Center for Applied Medical Research, IdiSNA (Navarra Institute for Health Research), University of Navarra, 31009 Pamplona, Navarra, Spain

    2 shared publications
  • Estefanía Rodríguez

    Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain

    2 shared publications
  • Mirari Echepare

    Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red, Cáncer (CIBERONC), Madrid, Spain; Navarra Health Institute (IDISNA), Pamplona, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain

    2 shared publications

Latest Publications

  • Open Access

    An Immunothrombotic Extracellular Vesicle mRNA Profile Associated with Thrombosis in Lung Adenocarcinoma

    by María Marcos-Jubilar, Clara Fernandez-Arias, Carmen Herrero-Carrasco, Elizabeth Guruceaga, Karmele Valencia, Pablo Elizalde, Susana Inoges, Ramón Lecumberri, Josune Orbe

    Venous thromboembolism (VTE) significantly impacts lung adenocarcinoma outcomes, yet current predictive tools lack precision. We investigated plasma extracellular vesicle (EV) mRNA as a liquid biopsy source to identify a pro-thrombotic molecular profile in VTE patients. Within a prospective cohort of 260 patients, we performed a retrospective nested case–control study, matching 10 VTE cases with 11 thrombosis-free controls. Plasma EV-RNA was analyzed via high-throughput sequencing. Differentially expressed genes (DEGs) were integrated with functional enrichment and explored across public non-cancer VTE datasets, buffy coat samples, and cell lines. RNA-seq identified 483 DEGs within the VTE patient EV compartment, predominantly linked to neutrophil degranulation (NETosis), inflammation, and coagulation. We identified a set of EV-associated candidate genes (SELP, ELANE, MYL9, DNASE1L3) distinguishing cancer-associated thrombosis from non-malignant VTE, along with transcripts (TFPI, FCGR2A) selectively enriched within the EV compartment relative to circulating blood cells. P-selectin (SELP) was the only significantly increased marker, providing the strongest complementary support at the protein level. This molecular state was detectable prior to the occurrence of VTE. Plasma EVs capture a multicellular mRNA profile, reflecting the systemic immunothrombotic activation in lung adenocarcinoma. Despite sample size limitations, these findings should be considered exploratory and hypothesis-generating, but they suggest the EV-derived mRNA in combination with circulating markers such as SELP may provide a framework for future studies aimed at improving risk stratification.

  • Establishment single lung tumors through orthotopic injection

    by Beñat Picabea, Céline Clémenson, Mirari Echepare, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Michele Mondini, Karmele Valencia

  • Intracardiac injection as a metastatic model in lung cancer

    by Mirari Echepare, Beñat Picabea, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Karmele Valencia

  • Open Access

    The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    by Karmele Valencia, Oihane Erice, Kaja Kostyrko, Simone Hausmann, Elizabeth Guruceaga, Anuradha Tathireddy, Natasha M. Flores, Leanne C. Sayles, Alex G. Lee, Rita Fragoso, et al.

    Few therapies are currently available for patients with KRAS-driven cancers, highlighting the need to identify new molecular targets that modulate central downstream effector pathways. Here we found that the microRNA (miRNA) cluster including miR181ab1 is a key modulator of KRAS-driven oncogenesis. Ablation of Mir181ab1 in genetically engineered mouse models of Kras-driven lung and pancreatic cancer was deleterious to tumor initiation and progression. Expression of both resident miRNAs in the Mir181ab1 cluster, miR181a1 and miR181b1, was necessary to rescue the Mir181ab1-loss phenotype, underscoring their nonredundant role. In human cancer cells, depletion of miR181ab1 impaired proliferation and 3D growth, whereas overexpression provided a proliferative advantage. Lastly, we unveiled miR181ab1-regulated genes responsible for this phenotype. These studies identified what we believe to be a previously unknown role for miR181ab1 as a potential therapeutic target in 2 highly aggressive and difficult to treat KRAS-mutated cancers.